Sarcoidosis — Research Summary
Printed from RareWays (rareways.com.au) on 26 July 2026
For general awareness only. Not medical advice. Discuss all care options with your healthcare team.
5 Most Recent Research Articles
- 1.
Monitoring the safety of the adjuvanted human papillomavirus vaccine HPV-16/18-AS04 in association with pregnancy and potential immune-related diseases in China: A retrospective observational cohort study.
Yang Junting et al. — Human vaccines & immunotherapeutics (1 December 2026)
https://pubmed.ncbi.nlm.nih.gov/42348585/
- 2.
Occupational category, job type, and sarcoidosis: Findings from a French multicenter study.
Lhote Raphael et al. — Pulmonology (1 December 2026)
https://pubmed.ncbi.nlm.nih.gov/42339517/
- 3.
scRNA-seq based gene and cell dynamics behind the formation of the non-caseating granulomas.
Singh Neha et al. — Computational biology and chemistry (1 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42001827/
- 4.
Targeting CXCR6 suppresses granuloma formation and pulmonary fibrosis through inhibiting Th17 responses in sarcoidosis.
Han Yueyin et al. — International immunopharmacology (1 August 2026)
https://pubmed.ncbi.nlm.nih.gov/42143504/
- 5.
Cutaneous Equine Sarcoidosis: A Case Series and Investigation Into a Potential Association With Equine Gammaherpesviruses-2 and -5 in 30 Equids.
Garandeau Celine et al. — Veterinary dermatology (3 July 2026)
https://pubmed.ncbi.nlm.nih.gov/42399093/
Clinical Trials — Australian Sites
Ask your doctor whether you or your child may be eligible for any of these trials.
- 1.
Catheter Ablation Versus Anti-arrhythmic Drugs for Ventricular Tachycardia
Active (not recruiting) — Na — Western Sydney Local Health District
https://clinicaltrials.gov/study/NCT05524077
Source: RareWays research directory. Data from PubMed, Europe PMC, OpenAlex, ClinicalTrials.gov.
Always verify information with your healthcare team before making any decisions about your care.
Sarcoidosis
Sarcoidosis is a chronic inflammatory disease characterised by the formation of granulomas that can affect any organ but most commonly the lungs and lymph nodes. Its cause remains unknown. Many patients experience spontaneous remission, but a significant minority develop progressive organ damage requiring long-term treatment.
Most Recent Research
Human papillomavirus (HPV) infection causes cervical cancer. The objective of the study is to monitor AS04-adjuvanted HPV-16/18 vaccine (Cervarix, GSK) safety in a real-world setting in China, using electronic health records from the Yinzhou Regional Health Information Platform (YRHIP). This retrospective observational cohort study included all permanent residents (males and females) aged 9-45 y with ≥12 months continuous YRHIP registration between 1 January 2010 and 31 December 2020. The study analyzed demographic information, diagnoses coded using International Classification of Diseases 10th Revision for potential immune-mediated diseases (pIMD) and pregnancy-related outcomes, and HPV vaccination records. Of 1,002,399 participants in the YRHIP, 891,463 met the eligibility criteria. In the age group 9-45 y, uptake of AS04-adjuvanted HPV-16/18 vaccine was 11.95/1000 persons. The incidence density for other spondylopathies, sarcoidosis, and pulmonary sarcoidosis was significantly higher in females vaccinated with any dose of AS04-adjuvanted HPV-16/18 vaccine compared with females who did not receive HPV vaccination during the study period (p < .01). No causal relationship could be established due to confounding factors and potential misclassification. The GSK safety database or EudraVigilance database were reviewed and no signals associated with these events were identified. For other pIMDs and adverse pregnancy-related outcomes, no increased incidence was found for vaccinated females. While certain pIMDs demonstrated an increased incidence in vaccinated individuals, no causal association was confirmed. Further research is needed to address residual confounding factors and validate findings. The overall safety profile of AS04-adjuvanted HPV-16/18 vaccination in Chinese girls and women aged 9-45 y could be considered as favorable.Clinical Trial Registration:Retrospectively registered on http://www.chinadrugtrials.org.cn/index.html, 22 March 2021, registration number CTR20210523.
Common Questions
What is Sarcoidosis?
Sarcoidosis is a chronic inflammatory disease characterised by the formation of granulomas that can affect any organ but most commonly the lungs and lymph nodes. Its cause remains unknown. Many patients experience spontaneous remission, but a significant minority develop progressive organ damage requiring long-term treatment.
How many clinical trials are available for Sarcoidosis?
RareWays currently indexes 223 clinical trials for Sarcoidosis, of which 48 are actively recruiting. Trial availability changes as new studies are registered — check the trials tab for current status.
Where does the research data for Sarcoidosis come from?
RareWays aggregates research from PubMed, Europe PMC, OpenAlex, and ClinicalTrials.gov. Data is updated regularly by Rocky, RareWays' automated research engine. All articles and trials link directly to their original sources.
Get research updates
Monthly email when new findings are published for Sarcoidosis.
No spam. Unsubscribe any time. Not medical advice.
This information is for general awareness only.
For guidance specific to your situation, please speak with your healthcare team.